These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20952061)

  • 1. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
    Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
    [No Abstract]   [Full Text] [Related]  

  • 2. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman J
    Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate--a new oral targeted therapy.
    Savage DG; Antman KH
    N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
    Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Urbano-Ispizua A; Frauendorfer K
    Leukemia; 2007 Mar; 21(3):383-6. PubMed ID: 17311065
    [No Abstract]   [Full Text] [Related]  

  • 7. Gleevec (STI-571) for chronic myeloid leukemia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):49-50. PubMed ID: 11402258
    [No Abstract]   [Full Text] [Related]  

  • 8. [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
    Kodama Y; Kami M
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):577-81. PubMed ID: 20414010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z; Wang C; Xu X; Feng W
    Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH; Ballard EE
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Barbour V
    Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Rajaratnam G; Edwards J
    Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
    [No Abstract]   [Full Text] [Related]  

  • 13. Position paper on imatinib mesylate in chronic myeloid leukaemia.
    O'Brien SG; Rule SA
    Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib for chronic myeloid leukaemia: a NICE mess.
    O'Brien SG
    Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
    [No Abstract]   [Full Text] [Related]  

  • 15. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
    Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
    Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic myelogenous leukemia therapy beyond imatinib.
    Deininger M
    Clin Adv Hematol Oncol; 2010 Mar; 8(3):178-80. PubMed ID: 20400933
    [No Abstract]   [Full Text] [Related]  

  • 18. [Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia].
    Nielsen JL
    Ugeskr Laeger; 2003 May; 165(20):2111. PubMed ID: 12812107
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies].
    Yagasaki F
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():505-10. PubMed ID: 17474456
    [No Abstract]   [Full Text] [Related]  

  • 20. [Management of chronic myeloid leukemia by imatinib].
    Kizaki M
    Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.